MiMedx stock price target raised to $12 from $11 at Cantor Fitzgerald

Published 31/07/2025, 13:54
MiMedx stock price target raised to $12 from $11 at Cantor Fitzgerald

Investing.com - Cantor Fitzgerald raised its price target on MiMedx Group (NASDAQ:MDXG) to $12.00 from $11.00 on Thursday, while maintaining an Overweight rating on the stock. With the stock currently trading at $6.52, InvestingPro analysis suggests MDXG is undervalued, supported by a "GREAT" overall financial health score of 3.46/5.

The price target increase follows MiMedx’s second-quarter revenue beat and raised 2025 revenue guidance. The company reported revenue of $98.6 million, exceeding both Cantor’s estimate of $91.4 million and the FactSet consensus of $90.4 million.

MiMedx achieved approximately 13% year-over-year growth, driven by its wound portfolio, which increased about 12% year-over-year to $64.5 million. The surgical segment grew approximately 15% year-over-year to $34.1 million.

The company ended the quarter with approximately $100.0 million in net cash, up from roughly $88 million in the first quarter of 2025 and $50 million in the year-ago period. Cantor Fitzgerald noted that MiMedx’s cash generation profile is "underappreciated."

Cantor Fitzgerald believes MiMedx is positioned to gain market share in 2026 and represents an undervalued opportunity, recommending investors buy the stock even on today’s strength.

In other recent news, MiMedx Group Inc reported robust financial results for the second quarter of 2025. The company achieved earnings per share (EPS) of $0.10, which is double the forecasted $0.05. Additionally, MiMedx surpassed revenue expectations, reporting $98.61 million compared to the anticipated $90.62 million. These results indicate strong company performance and have been met with positive investor sentiment. The company’s financial achievements have been noted by analysts, though no specific upgrades or downgrades were mentioned in recent reports. These developments highlight MiMedx’s ability to exceed market expectations in both earnings and revenue. Investors are likely to keep a close watch on the company’s future performance based on these recent results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.